<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39315349</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1715-1635</ISSN><JournalIssue CitedMedium="Print"><Volume>157</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC</Title><ISOAbbreviation>Can Pharm J (Ott)</ISOAbbreviation></Journal><ArticleTitle>Pharmacists' prescribing of opioids in Nova Scotia under Health Canada's Controlled Drugs and Substances Act temporary exemption during the COVID-19 pandemic.</ArticleTitle><Pagination><StartPage>240</StartPage><EndPage>245</EndPage><MedlinePgn>240-245</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/17151635241267008</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watema-Lord</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Dalhousie University, Halifax, Nova Scotia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sketris</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Dalhousie University, Halifax, Nova Scotia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neville</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Drug Utilization Pharmacist &amp; Pharmacy Research Coordinator, Nova Scotia Health, Halifax, Nova Scotia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asbridge</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Community Health &amp; Epidemiology, Dalhousie University, Halifax, Nova Scotia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanyal</LastName><ForeName>Chiranjeev</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3677-8036</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, Dalhousie University, Halifax, Nova Scotia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can Pharm J (Ott)</MedlineTA><NlmUniqueID>101257110</NlmUniqueID><ISSNLinking>1715-1635</ISSNLinking></MedlineJournalInfo><CoiStatement>R.W.-L., I.S., C.S., H.N. and M.A. declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>4</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39315349</ArticleId><ArticleId IdType="pmc">PMC11418243</ArticleId><ArticleId IdType="doi">10.1177/17151635241267008</ArticleId><ArticleId IdType="pii">10.1177_17151635241267008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sanyal C. Economic burden of opioid crisis and the role of pharmacist-led interventions. J Am Pharm Assoc 2021;61:e70-74.</Citation><ArticleIdList><ArticleId IdType="pubmed">33279425</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet Regional Health-Americas. Opioid crisis: addiction, overprescription, and insufficient primary prevention. Lancet Reg Health Am 2023;23:100557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10366477</ArticleId><ArticleId IdType="pubmed">37497399</ArticleId></ArticleIdList></Reference><Reference><Citation>
Government of Canada. Opioid and stimulant-related harms in Canada. 2024. Available: https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/graphs.html?ind=4&amp;unit=1 (accessed Jun. 13, 2024).</Citation></Reference><Reference><Citation>Wilson MN, Hayden JA, Rhodes E, Robinson A, Asbridge M. Effectiveness of prescription monitoring programs in reducing opioid prescribing, dispensing, and use outcomes: a systematic review. J Pain 2019;20:1383-93.</Citation><ArticleIdList><ArticleId IdType="pubmed">31059823</ArticleId></ArticleIdList></Reference><Reference><Citation>Comeau E, Bonn M, Wildeman S, Herder M. ‘More of the same, but worse than before’: a qualitative study of the challenges encountered by people who use drugs in Nova Scotia, Canada during COVID-19. PLoS One 2023;18:e0283979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10075390</ArticleId><ArticleId IdType="pubmed">37018353</ArticleId></ArticleIdList></Reference><Reference><Citation>
Government of Canada. Chief Public Health Officer of Canada’s report on the state of public health in Canada. 2020. Available: https://www.canada.ca/en/public-health/corporate/publications/chief-public-health-officer-reports-state-public-health-canada/from-risk-resilience-equity-approach-covid-19.html#ack (accessed Sep. 11, 2021).</Citation></Reference><Reference><Citation>Lebrasseur A, Fortin-Bédard N, Lettre J, et al.. Impact of the COVID-19 pandemic on older adults: rapid review. JMIR Aging 2021;4:e26474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043147</ArticleId><ArticleId IdType="pubmed">33720839</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon M, Nadigel J, Thompson E, Glazier RH. Informing Canada’s health system response to COVID-19: priorities for health services and policy research. Healthc Policy 2020;16:112-24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7435075</ArticleId><ArticleId IdType="pubmed">32813643</ArticleId></ArticleIdList></Reference><Reference><Citation>Breton M, Marshall EG, Deslauriers V, et al.. COVID-19—an opportunity to improve access to primary care through organizational innovations? A qualitative multiple case study in Quebec and Nova Scotia (Canada). BMC Health Serv Res 2022;22:759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9177136</ArticleId><ArticleId IdType="pubmed">35676668</ArticleId></ArticleIdList></Reference><Reference><Citation>
CBC News. About 120 surgeries postponed over 4 days in N.S. amid Omicron wave. 2022. Available: https://www.cbc.ca/news/canada/nova-scotia/surgeries-nova-scotia-postponed-covid-1.6310864 (accessed Mar. 1, 2024).</Citation></Reference><Reference><Citation>
Canadian Drug Policy Coalition. CDSA exemption and interpretive guide for controlled substances. 2020. Available: https://drugpolicy.ca/cdsa-exemption-and-interpretive-guide-for-controlled-substances (accessed Mar. 1, 2024).</Citation></Reference><Reference><Citation>
Canada.ca. Frequently asked questions: exemptions for practitioners and pharmacists prescribing and providing controlled substances, and for patients, during the coronavirus pandemic. 2021. Available: https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/policy-regulations/policy-documents/section-56-1-class-exemption-patients-pharmacists-practitioners-controlled-substances-covid-19-pandemic/frequently-asked-questions.html (accessed Mar. 1, 2024).</Citation></Reference><Reference><Citation>
Government of Canada. Subsection 56(1) class exemption for patients, practitioners and pharmacists prescribing and providing controlled substances in Canada. 2021. Available: https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/policy-regulations/policy-documents/section-56-1-class-exemption-patients-pharmacists-practitioners-controlled-substances-covid-19-pandemic.html (accessed Mar. 1, 2024).</Citation></Reference><Reference><Citation>
Pharmacy practice regulations. 2023. Available: https://novascotia.ca/just/regulations/regs/pharmprc.htm#TOC3_3 (accessed Mar. 1, 2024).</Citation></Reference><Reference><Citation>Sketris I, Bishop A, Ramsey T, Isenor J, Sanyal C. Expanding the scope of community pharmacy practice in Nova Scotia: impacts on provincial COVID-19 response. Health Reform Observer—Observatoire des Réformes de Santé 2023;11(1):Article 5. doi:10.13162/hro-ors.v11i1.5403.</Citation><ArticleIdList><ArticleId IdType="doi">10.13162/hro-ors.v11i1.5403</ArticleId></ArticleIdList></Reference><Reference><Citation>
Standards of practice: prescribing drugs. 2024. Available: https://www.nspharmacists.ca/wp-content/uploads/2014/11/SOP_PrescribingDrugs_May2024.pdf (accessed May 2, 2024).</Citation></Reference><Reference><Citation>
Prescription Monitoring Program. Nova Scotia prescription monitoring program. 2024. Available: https://www.nspmp.ca (accessed Mar. 1, 2024).</Citation></Reference><Reference><Citation>
Prescription monitoring program: monitored drugs. 2024. Available: https://www.nspmp.ca/about-nspmp/monitored-drugs (accessed Mar. 1, 2024).</Citation></Reference><Reference><Citation>
Controlled Drugs and Substances Act. 2024. Available: https://laws-lois.justice.gc.ca/eng/acts/c-38.8/ (accessed Mar. 1, 2024).</Citation></Reference><Reference><Citation>Jimoh KO, Matthews DC, Brillant M, Sketris I. Pattern of opioid analgesic prescription for adults by dentists in Nova Scotia, Canada. JDR Clin Trans Res 2018;3:203-11.</Citation><ArticleIdList><ArticleId IdType="pubmed">30931773</ArticleId></ArticleIdList></Reference><Reference><Citation>
NSPMP. Prescription monitoring program: frequently asked questions. 2024. Available: https://www.nspmp.ca/frequently-asked-questions (accessed Mar. 1, 2024).</Citation></Reference><Reference><Citation>
Government of Canada. Forward sortation area—definition. 2015. Available: https://ised-isde.canada.ca/site/office-superintendent-bankruptcy/en/statistics-and-research/forward-sortation-area-fsa-and-north-american-industry-classification-naics-reports/forward-sortation-area-definition (accessed Mar. 1, 2024).</Citation></Reference><Reference><Citation>Jones W, Kaoser R, Rudoler D, Fischer B. Trends in dispensing of individual prescription opioid formulations, Canada 2005-2020. J Pharm Policy Pract 2022;15:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8966300</ArticleId><ArticleId IdType="pubmed">35351208</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgundvaag B, McLeod S, Khuu W, Varner C, Tadrous M, Gomes T. Opioid prescribing and adverse events in opioid-naive patients treated by emergency physicians versus family physicians: a population-based cohort study. CMAJ Open 2018;6:E110-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5878958</ArticleId><ArticleId IdType="pubmed">29506986</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy AR, O’Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003;10:67-71.</Citation><ArticleIdList><ArticleId IdType="pubmed">12879144</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>